|
Accession number;99A0203852
|
| Title;The difference in the treatment strategies between Japan and US and Europe. Lung Cancer. |
| Author;
GOYA TOMOYUKI
(Kyorin Univ., Fac. of Med.)
KAWAJI RIKEN
(Kyorin Univ., Fac. of Med.)
KOBAYASHI YUKARI
(Kyorin Univ., Fac. of Med.)
YANAGIDA OSAMU
(Kyorin Univ., Fac. of Med.)
SEKIHARA TADASHI
(Kyorin Univ., Fac. of Med.)
|
Journal Title;Japanese Journal of Cancer and Chemotherapy
|
Journal Code:Z0938A
|
ISSN:0385-0684
|
|
VOL.26;NO.1;PAGE.49-53(1999)
|
| Figure&Table&Reference;TBL.2, REF.11 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The five year survival rate of lung cancer patients is only 10% in Japan. The staging system of c-TNM is more important than p-TNM when deciding treatment modality for lung cancer. Compared to other solid cancers, neoadjuvant therapy in lung cancer treatment has a more important position. A clinical protocol study should be carried out with the idea of "intent to treat" and medical oncology will play a more important role in the treatment of lung cancer. (author abst.) |
|
|
|
Related Articles;
|
|
